A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 99
Updated:3/21/2019
Start Date:February 22, 2016
End Date:October 15, 2021
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors

This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study
to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and
immunogenicity of Durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in Adult
Subjects with selected advanced solid tumors and the combination of durvalumab and
monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and
monalizumab (IPH2201) with biological agent administered to subjects with recurrent or
metastatic colorectal cancer (CRC).

The study consists of 3 parts: dose escalation (Part 1), dose expansion (Part 2), and dose
exploration (Part 3). Part 1 will evaluate dose escalation of durvalumab in combination with
monalizumab in adult subjects with select advanced solid tumor malignancies. Part 2 will
evaluate further the identified dose of durvalumab in combination with monalizumab from Part
1 in adult subjects with select advanced solid tumor malignancies. Part 3 will evaluate dose
exploration of durvalumab in combination with monalizumab and standard of care systemic
therapy with or without biological agent, and monalizumab in combination with biological
agent in adult subjects with CRC.

Inclusion Criteria:

1. Subjects must have histologic documentation of advanced recurrent or metastatic
cancer.

2. Subjects must be at the recurrent/metastatic setting, with selected advanced solid
tumors.

3. Subjects must have at least one lesion that is measurable by RECIST v1.1

4. Part 3, Dose exploration, CRC subjects can be treatment naïve but should not have
received more than two line of systemic therapy in the recurrent/metastatic setting.

Exclusion Criteria

1. Prior treatment with immunotherapy agents. Prior treatment with antitumor vaccines may
be permitted upon discussion with the medical monitor.

2. Prior participation in clinical studies that include durvalumab alone or in
combination, where the study has registrational intent and the analyses for the
primary endpoint have not yet been completed

3. Receipt of any conventional or investigational anticancer therapy within 4 weeks prior
to the first dose of study treatment

4. Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer
treatment. Concurrent use of hormones for non-cancer-related conditions is acceptable.
We found this trial at
27
sites
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Blacktown,
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Newport Beach, California 92660
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Providence, RI
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials